LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Incyte Corp

Закрыт

СекторЗдравоохранение

86.84 0.67

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

86.12

Макс.

87.04

Ключевые показатели

By Trading Economics

Доход

247M

405M

Продажи

163M

1.2B

P/E

Средняя по отрасли

18.721

34.427

Прибыль на акцию

1.16

Рентабельность продаж

33.319

Сотрудники

2,617

EBITDA

277M

534M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-4.45% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

28 окт. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.9B

15B

Предыдущая цена открытия

86.17

Предыдущая цена закрытия

86.84

Новостные настроения

By Acuity

9%

91%

4 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Incyte Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 авг. 2025 г., 16:11 UTC

Главные движущие силы рынка

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 авг. 2025 г., 22:22 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

15 авг. 2025 г., 22:22 UTC

Обсуждения рынка

Target Is Falling Behind Its Peers -- Market Talk

15 авг. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

15 авг. 2025 г., 20:33 UTC

Обсуждения рынка

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 авг. 2025 г., 20:25 UTC

Отчет
Приобретения, слияния, поглощения

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 авг. 2025 г., 20:24 UTC

Отчет
Приобретения, слияния, поглощения

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 авг. 2025 г., 20:18 UTC

Отчет

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 авг. 2025 г., 19:14 UTC

Обсуждения рынка

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 авг. 2025 г., 19:12 UTC

Обсуждения рынка

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 авг. 2025 г., 18:32 UTC

Обсуждения рынка

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 авг. 2025 г., 17:33 UTC

Обсуждения рынка

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 авг. 2025 г., 17:23 UTC

Обсуждения рынка
Отчет

Deere's Earnings Appear to Be Troughing -- Market Talk

15 авг. 2025 г., 16:27 UTC

Отчет

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 авг. 2025 г., 16:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

15 авг. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

15 авг. 2025 г., 16:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

15 авг. 2025 г., 16:05 UTC

Приобретения, слияния, поглощения

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 авг. 2025 г., 15:52 UTC

Приобретения, слияния, поглощения

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 авг. 2025 г., 15:36 UTC

Обсуждения рынка

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 авг. 2025 г., 15:29 UTC

Отчет

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 авг. 2025 г., 15:29 UTC

Приобретения, слияния, поглощения

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 авг. 2025 г., 15:28 UTC

Отчет

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 авг. 2025 г., 15:24 UTC

Обсуждения рынка

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 авг. 2025 г., 15:08 UTC

Обсуждения рынка

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 авг. 2025 г., 14:38 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 авг. 2025 г., 14:37 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 авг. 2025 г., 14:37 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 авг. 2025 г., 14:36 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 авг. 2025 г., 14:33 UTC

Приобретения, слияния, поглощения

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Сравнение c конкурентами

Изменение цены

Incyte Corp Прогноз

Целевая цена

By TipRanks

-4.45% падение

Прогноз на 12 месяцев

Средняя 83.05 USD  -4.45%

Максимум 110 USD

Минимум 60 USD

Основано на мнении 20 аналитиков Wall Street, спрогнозировавших целевые цены для Incyte Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

20 ratings

11

Покупка

8

Удержание

1

Продажа

Техническая оценка

By Trading Central

59.52 / 62.66Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

4 / 374Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation